Last updated: April 4, 2025
Sponsor: CVRx, Inc.
Overall Status: Terminated
Phase
N/A
Condition
Chest Pain
Congestive Heart Failure
Hyponatremia
Treatment
Barostim™ System
Clinical Study ID
NCT05860348
360064-001
All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Patients can be included if they were implanted with a cardiac resynchronizationtherapy (CRT) device at least six months (180 days) prior to informed consent andare planned for a de novo Barostim System implantation. Patients must sign aninformed consent form before implantation with the Barostim System in order toparticipate in this study.
Exclusion
Exclusion Criteria:
- Patients cannot be enrolled and active in another (e.g. device, pharmaceutical, orbiological) clinical study unless approved by the CVRx Clinical department.
Study Design
Total Participants: 5
Treatment Group(s): 1
Primary Treatment: Barostim™ System
Phase:
Study Start date:
July 25, 2023
Estimated Completion Date:
December 11, 2024
Study Description
Connect with a study center
Aurora Denver Cardiology Associates
Aurora, Colorado 80012
United StatesSite Not Available
Florida Heart Rhythm Specialists
Fort Lauderdale, Florida 33308
United StatesSite Not Available
Advanced Cardiology
Hackettstown, New Jersey 07840
United StatesSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.